



## **MEDIA RELEASE**

### **SAHPRA and the Sinopharm Vaccine**

**Embargo: Immediate release**

**Pretoria, 23 June 2021** – SAHPRA has received documentation for the Sinopharm vaccine developed by the China National Pharmaceutical Group in China.

SAHPRA will now commence with evaluating the data in assessing the efficacy of the vaccine

#### **Issued by:**

Dr Boitumelo Semete

**CEO**

**Boitumelo.semete@sahpra.org.za**

**For further enquiries /information contact:**

**Media contact:**

Mr Yuven Gounden

Cell: 066 1202 669

**E-mail: [yuveng@sahpra.org.za](mailto:yuveng@sahpra.org.za)**

## **About SAHPRA:**

SAHPRA is tasked with regulating (monitoring, evaluating, investigating, inspecting and registering) all health products. This includes clinical trials, complementary medicines, medical devices and in-vitro diagnostics (IVDs). Furthermore, SAHPRA has the added responsibility of overseeing radiation control in South Africa. SAHPRA's mandate is outlined in the Medicines and Related Substances Act (Act No 101 of 1965 as amended) as well as the Hazardous Substances Act (Act No 15 of 1973).

SAHPRA has three pillars to ensure that medicines, medical devices and IVDs meet the requisite standards to protect the health and well-being of all who reside in South Africa:

- Safety
- Efficacy
- Quality

It is these three pillars that define the ethos of SAHPRA.